Solvonis Therapeutics (J4I) Stock Price & Analysis

0 Followers

J4I Stock Chart & Stats

€0.01€0.00(0.00%)

At close: Oct 17 2:00 AM GMT+2

No data to display

Day’s Range: EUR 0.01 - EUR 0.01
52-Week Range: EUR 0.01 - EUR 0.16
Previous Close: EUR 0.01
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 8.52M
Enterprise Value: EUR 11.32M
Total Cash (Recent Filing): EUR 1.72M
Total Debt (Recent Filing): EUR 75.00K
Price to Earnings (P/E): ―
Beta: -2.13
Next Earnings: Jun 30, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt lowers the company’s fixed financial burden and reduces exposure to refinancing or interest-payment pressure. This gives Solvonis greater flexibility to preserve resources, pursue development priorities, or absorb operating volatility while it works toward a sustainable business model.

Positive Equity Base

A positive and expanding equity base provides an important solvency buffer despite ongoing losses. It can support continued operations and strategic investment over the medium term, while giving the company more financial resilience than a business already operating with negative shareholder capital.

Cash Burn Tracks Losses

Although cash generation is negative, its broad alignment with reported losses indicates that the cash shortfall is not being driven by a substantially larger underlying drain. That relationship may make future funding needs more predictable if operating performance begins to improve.

Bears Say

Persistent Losses

Recurring operating and net losses show that Solvonis has not yet demonstrated a profitable operating model. Continued losses can consume the company’s financial resources, weaken equity over time, and limit its ability to fund development or expansion without additional capital.

Revenue Collapse

Near-zero recent revenue materially weakens evidence of product traction, commercial scale, or recurring customer demand. Without a dependable revenue base, the company has limited internal funding capacity and remains highly dependent on future business execution to establish sustainable earnings.

Negative Free Cash Flow

Persistent operating cash burn and worsening free cash flow increase the resources required to keep the business running. Unless cash generation improves, Solvonis may need to rely on financing or reduce investment, creating ongoing pressure on its ability to develop and commercialize its activities.

Solvonis Therapeutics News

Solvonis moves to add Portuguese sites to Phase 3 alcohol addiction trial

Solvonis Therapeutics ( ($GB:SVNS) ) has shared an announcement. Solvonis Therapeutics has signed a Memorandum of Understanding with Portugal’s National Addiction Institute, ICAD, and local clinical partner Panegreen to assess

1M agoJ4I SVNS

Solvonis plans investor briefing as it advances pipeline in addiction and mental health

Solvonis Therapeutics ( ($GB:SVNS) ) just unveiled an announcement. Solvonis Therapeutics, a London-based late clinical-stage biopharmaceutical firm listed on the LSE, develops small-molecule therapies for central nervous system disorders with

1M agoJ4I SVNS

Solvonis boosts equity base with admission of over 1.09bn new shares

Solvonis Therapeutics ( ($GB:SVNS) ) has provided an update. Solvonis Therapeutics has admitted 1,093,333,333 new ordinary shares to trading on the London Stock Exchange’s Main Market, increasing its total issued

1M agoJ4I SVNS

Solvonis Advances CNS Pipeline as Cash Tightens and New Funding Arrives

Solvonis Therapeutics ( ($GB:SVNS) ) has issued an update. Solvonis reported unaudited interim results for the six months to 30 June 2026, highlighting clinical progress on its CNS pipeline despite

1M agoJ4I SVNS

Solvonis touts ketamine-based AUD candidate as data sharpen European and U.S. expansion plans

An announcement from Solvonis Therapeutics ( ($GB:SVNS) ) is now available. Solvonis Therapeutics plc, a London-listed biopharmaceutical company, is developing small-molecule therapies for central nervous system disorders, with a particular

1M agoJ4I SVNS

Solvonis Wins Key European Patent for Next-Generation PTSD Drug SVN-114

Solvonis Therapeutics ( ($GB:SVNS) ) just unveiled an update. Solvonis Therapeutics has secured a key intellectual property milestone, with the European Patent Office issuing a notice of allowance for a

2M agoJ4I SVNS

Solvonis raises £1.3m to drive CNS pipeline and appoints new broker

Solvonis Therapeutics ( ($GB:SVNS) ) has shared an update. Solvonis Therapeutics has conditionally raised £1.3 million via a discounted placing of 1,083,333,333 new shares, bringing a new UK institutional investor

2M agoJ4I SVNS

Solvonis Steps Up U.S. Investor Push With Water Tower Research Conference

Solvonis Therapeutics ( ($GB:SVNS) ) has shared an announcement. Solvonis Therapeutics will showcase its CNS-focused drug pipeline and capital-efficient development strategy at the Water Tower Research Virtual Insights Conference on

3M agoJ4I SVNS

Solvonis’ SVN-015 Cleared for Further NIDA Studies in Stimulant Use Disorder

The latest update is out from Solvonis Therapeutics ( ($GB:SVNS) ). Solvonis Therapeutics has reported encouraging initial preclinical data for its discovery-stage candidate SVN-015, a small molecule designed to modulate

3M agoJ4I SVNS

Solvonis Wins U.S. Research Coverage as AUD Pipeline Targets Large CNS Market

Solvonis Therapeutics ( ($GB:SVNS) ) just unveiled an announcement. Solvonis Therapeutics has been initiated under research coverage by U.S.-based Water Tower Research, which profiles the company’s clinical-stage CNS portfolio, especially

4M agoJ4I SVNS

J4I FAQ

What was Solvonis Therapeutics’s price range in the past 12 months?

Solvonis Therapeutics lowest stock price was €0.01 and its highest was €0.16 in the past 12 months.

What is Solvonis Therapeutics’s market cap?

Solvonis Therapeutics’s market cap is €8.52M.

When is Solvonis Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Solvonis Therapeutics’s earnings last quarter?

Solvonis Therapeutics released its earnings results on Sep 30, 2026. The company reported €0 earnings per share for the quarter.

Is Solvonis Therapeutics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Solvonis Therapeutics pay dividends?

Solvonis Therapeutics does not currently pay dividends.

What is Solvonis Therapeutics’s EPS estimate?

Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Solvonis Therapeutics have?

Solvonis Therapeutics has 7,899,737,000 shares outstanding.

What happened to Solvonis Therapeutics’s price movement after its last earnings report?

Solvonis Therapeutics reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Solvonis Therapeutics?

Currently, no hedge funds are holding shares in DE:J4I

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description